Furthermore, many trials demonstrated the clinical benefits and favorable tolerability of anti-PD-1/PD-L1 for previously treated with chemotherapy in NSCLC patients (11–14). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.